Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis.
作者信息
Parrondo Ricardo D, Sam Keren, Rasheed Ahsan, Alegria Victoria, Sher Taimur, Roy Vivek, Chanan-Khan Asher, Ailawadhi Sikander
机构信息
Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
出版信息
Blood Cancer J. 2022 Apr 19;12(4):66. doi: 10.1038/s41408-022-00662-0.
Abstract
摘要
相似文献
1
Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis.
Blood Cancer J. 2022 Apr 19;12(4):66. doi: 10.1038/s41408-022-00662-0.
2
The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
BioDrugs. 2022 Nov;36(6):773-780. doi: 10.1007/s40259-022-00557-3. Epub 2022 Sep 27.
3
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Future Oncol. 2022 Jan;18(3):277-289. doi: 10.2217/fon-2021-1090. Epub 2021 Dec 2.
4
[New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment].
Bull Cancer. 2022 Feb;109(2):113-114. doi: 10.1016/j.bulcan.2021.10.007. Epub 2022 Jan 19.
5
FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.
Clin Cancer Res. 2022 May 2;28(9):1759-1764. doi: 10.1158/1078-0432.CCR-21-3803.
6
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.
Int J Hematol. 2023 May;117(5):729-737. doi: 10.1007/s12185-023-03538-6. Epub 2023 Jan 24.
7
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
8
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin. 2021 Oct;37(10):1779-1788. doi: 10.1080/03007995.2021.1953456. Epub 2021 Jul 23.
9
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Leuk Res. 2023 Jun;129:107074. doi: 10.1016/j.leukres.2023.107074. Epub 2023 Apr 3.
10
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Br J Haematol. 2024 Apr;204(4):1293-1299. doi: 10.1111/bjh.19302. Epub 2024 Jan 23.
引用本文的文献
1
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.
Front Immunol. 2023 Feb 20;14:1101495. doi: 10.3389/fimmu.2023.1101495. eCollection 2023.
2
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
EJHaem. 2022 Sep 30;3(4):1270-1276. doi: 10.1002/jha2.572. eCollection 2022 Nov.
3
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Blood. 2023 Feb 16;141(7):756-765. doi: 10.1182/blood.2022017848.
4
Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy.
Blood Cancer J. 2022 Sep 6;12(9):130. doi: 10.1038/s41408-022-00725-2.
5
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges.
Blood Lymphat Cancer. 2022 Aug 29;12:119-136. doi: 10.2147/BLCTT.S327016. eCollection 2022.
6
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Front Immunol. 2022 Jun 10;13:927153. doi: 10.3389/fimmu.2022.927153. eCollection 2022.
Zotero 插件